How much do blood-based biomarkers help in diagnosing Alzheimer’s disease? Quite a lot, according to scientists led by Albert Puig Pijoan and Marc Suárez-Calvet at the Hospital del Mar in Barcelona, ...
In the latest development on diagnostic methods for Alzheimer’s disease going mainstream, the U.S. Food and Drug Administration approved clinical use of Lantheus’ tau PET tracer florquinitau, aka ...
Two groups of scientists have found that the same protein can have opposing effects on α-synuclein pathology. Microglia eliminate α-synuclein from neurons by “trogocytosis.” Silencing the glycoprotein ...
Anti-amyloid immunotherapies come with a risk of serious brain hemorrhage, which can be mitigated via monitoring for amyloid-related imaging abnormalities (ARIA) via MRI scans. Early signs of edema ...
The tau locus comes in two major genetic configurations, the H1 and H2 haplotypes. The latter carries a stretch of DNA, including the tau gene, that is flipped in orientation. As it turns out, a ...
Also the 24th Alzheimer's Disease and Related Disorders Annual convention of the Dementia Society of the Philippines ...
Past AlzForum Coverage: Human Amyloid Imaging 2013 Solanezumab Selected for Alzheimer’s A4 Prevention Trial HAI—Spotlight on Tau Tracers at Human Amyloid Imaging Meeting HAI—Amyloid Imaging in the ...
Tau, α-Synuclein Spread: Crazy Stuff—How Might It Work? Like Star Born of Supernova, Plaque Born of Exploded Neuron? Can Dousing PyroGlu-Aβ Treat Alzheimer’s Disease? Field Ramps Up "Mini" Mouse MRI ...
Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...
Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results